AAIPharma, Cortria Sign Drug Delivery Deal

AAIPharma and Cortria Corp. have signed a deal granting Cortria the right to use AAIPharma’s proprietary, controlled release oral drug delivery technology known as ProCR in conjunction with Cortria’s TRIA-662 drug candidate.
 
ProCR is a novel controlled-release technology developed by AAIPharma for use with orally administered drug products. TRIA-662 is Cortria’s lead drug candidate, currently in Phase II clinical development for dyslipidemia. In preliminary human studies, TRIA-662 has shown the potential to provide the benefits for niacin therapy without causing skin flushing, a common, use-limiting side effect of niacin agents.
 
“We believe TRIA-662 is one of the most exciting drug candidates in the cardiovascular pipeline today and we are pleased to work with Cortria to help develop this product candidate for patients with dyslipidemia,” said Lee Karras, senior vice president of Global Pharmaceutical Services at AAIPharma.  “Our goal is to work with companies like Cortria who have best-in-class therapeutic candidates and who can further benefit from best-in-class oral drug delivery solutions to maximize therapeutic performance.”
 
“AAIPharma has a rich history of providing oral solid dosage formulation development and has already been an outstanding partner for CORTRIA in the area of analytical services,” commented Daniel Grau, chief executive officer and vice chairman of Cortria. “Through this new agreement, we look forward to expanding our relationship with AAIPharma by applying its ProCR™ technology in the development of commercial formulations of TRIA-662.”
 
Terms of the license agreement have not been disclosed.